27 research outputs found
Structure-Templated Predictions of Novel Protein Interactions from Sequence Information
The multitude of functions performed in the cell are largely controlled by a set of carefully orchestrated protein interactions often facilitated by specific binding of conserved domains in the interacting proteins. Interacting domains commonly exhibit distinct binding specificity to short and conserved recognition peptides called binding profiles. Although many conserved domains are known in nature, only a few have well-characterized binding profiles. Here, we describe a novel predictive method known as domain–motif interactions from structural topology (D-MIST) for elucidating the binding profiles of interacting domains. A set of domains and their corresponding binding profiles were derived from extant protein structures and protein interaction data and then used to predict novel protein interactions in yeast. A number of the predicted interactions were verified experimentally, including new interactions of the mitotic exit network, RNA polymerases, nucleotide metabolism enzymes, and the chaperone complex. These results demonstrate that new protein interactions can be predicted exclusively from sequence information
SIRT1 catalytic activity has little effect on tumor formation and metastases in a mouse model of breast cancer.
The protein deacetylase SIRT1 has been implicated in the regulation of a large number of cellular processes that are thought to be required for cancer initiation and progression. There are conflicting data that make it unclear whether Sirt1 functions as an oncogene or tumor suppressor. To assess the effect of SIRT1 on the emergence and progression of mammary tumors, we crossed mice that harbor a point mutation that abolishes SIRT1 catalytic activity with mice carrying the polyoma middle T transgene driven by the murine mammary tumor virus promoter (MMTV-PyMT). The absence of SIRT1 catalytic activity neither accelerated nor blocked the formation of tumors and metastases in this model. There was a lag in tumor latency that modestly extended survival in Sirt1 mutant mice that we attribute to a delay in mammary gland development and not to a direct effect of SIRT1 on carcinogenesis. These results are consistent with previous evidence suggesting that Sirt1 is not a tumor promoter or a tumor suppressor
Modulation of Tumorigenesis by Dietary Intervention Is Not Mediated by SIRT1 Catalytic Activity
<div><p>The protein deacetylase SIRT1 is involved in the regulation of a large number of cellular processes that are thought to be required for cancer initiation and progression. Both SIRT1 activity and tumorigenesis can be influenced by dietary fat and polyphenolics. We set out to determine whether dietary modulations of tumorigenesis are mediated by SIRT1 catalytic functions. We introduced a mammary gland tumor-inducing transgene, MMTV-PyMT, into stocks of mice bearing a H355Y point mutation in the <i>Sirt1</i> gene that abolishes SIRT1 catalytic activity. Tumor latency was reduced in animals fed a high fat diet but this effect was not dependent on SIRT1 activity. Resveratrol had little effect on tumor formation except in animals heterozygous for the mutant <i>Sirt1</i> gene. We conclude that the effects of these dietary interventions on tumorigenesis are not mediated by modulation of SIRT1 catalytic activity.</p></div
Abrogation of SIRT1 catalytic activity does not prevent mammary tumor formation in the MMTV-PyMT mouse model of breast cancer.
<p><b>A</b>) Kaplan Meir plot showing the percentage of surviving animals over time. N= 10 mice per genotype. <i>Sirt1</i><sup>Y/Y</sup> animals had a significantly longer overall survival time than the <i>Sirt1</i><sup>+/+</sup> and the <i>Sirt1</i><sup>Y/+</sup> mice (p <0.01) <b>B</b>) Tumor burden as a proportion of total body weight at humane endpoint. All tumors were removed and weighed at necropsy. Points represent individual animals and bars represent the median. N=10 mice per genotype, all animals carried the MMTV-PyMT transgene.</p
High fat diet decreased tumor latency but did not affect survival in MMTV-PyMT transgenic mice.
<p><b>A, C, E)</b> Female mice of the indicated <i>Sirt1</i> genotypes carrying the MMTV-PyMT transgene were weaned onto high fat diet (HFD) or normal chow immediately following weaning. The mean number of mammary glands with a palpable mass was assessed at weekly intervals. Error bars indicate SEM. A significant difference in tumor latency was observed in <i>Sirt1</i><sup>+/+</sup> (P<0.0001) and <i>Sirt1</i><sup>Y/Y</sup> mice (P<0.0001). <b>B, D, F</b>) Kaplan Meier plot of surviving animals. N = 10 mice per <i>Sirt1</i> genotype per diet (□ standard diet,▪ HFD).</p
Loss of SIRT1 catalytic activity does not affect expression of the PyMT transgene.
<p>Representative immunohistochemical staining for Middle T Antigen in mammary glands of PyMT<sup>+</sup>/<i>Sirt1</i><sup>+/+</sup> and PyMT<sup>+</sup>/<i>Sirt1</i><sup>Y/Y</sup> mice collected at 6 weeks of age (scale bars equal to 100 μm). Arrows indicate areas of mammary intraepithelial neoplasia.</p
Loss of SIRT1 catalytic activity is associated with increase tumor latency
<p><b>A)</b> Kaplan Meir plot measuring the percentage of mice without any palpable mammary gland mass at the given age. N= 10 mice per genotype. There was a significant delay in the time at which the <i>Sirt1</i><sup>Y/Y</sup> developed their first detectable mass as compared to the <i>Sirt1</i><sup>+/+</sup> and the <i>Sirt1</i><sup>Y/+</sup> mice (P <0.01 and P < 0.05, respectively). <b>B)</b> The mean number of mammary glands with a palpable mass over time as measured at weekly intervals after birth. N= 10 mice per genotype. Error bars indicate SEM.</p
Loss of SIRT1 catalytic activity does not affect metastasis.
<p><b>A</b>) Mouse lungs displaying metastatic nodules (arrows) (H&E, left, scale bar 5 mm, right, scale bar 100 μm) and metastatic nodules stained via immunohistochemistry for polyoma middle T antigen and ERα (scale bar 100 μm) <b>B</b>) The number of individual metastatic nodules in whole lung H&E sections assessed at endpoint. Eight 10µm sections spaced 50µm apart were evaluated in each mouse. N=10 mice per genotype. Points represent individual animals and bars represent the mean number of metastatic nodules. <b>C</b>) The average number of individual metastatic nodules in whole lung H&E sections assessed at endpoint correlated with overall survival time in days. </p
Abolition of SIRT1 enzymatic activity results in blunted ductal morphogenesis in the mammary gland.
<p>Right panel, representative photographs of whole mounts of the 4<sup>th</sup> abdominal mammary gland in <i>Sirt1</i><sup>+/+</sup>, <i>Sirt1</i><sup>Y/+</sup> and <i>Sirt1</i><sup>Y/Y</sup> mice at eleven weeks of age (scale bar, 5mm). Left panel, a higher magnification view of the ductal network in representative mammary gland whole mounts of the 4<sup>th</sup> abdominal mammary gland in <i>Sirt1</i><sup>+/+</sup>, <i>Sirt1</i><sup>Y/+</sup> and <i>Sirt1</i><sup>Y/Y</sup> mice at eleven weeks of age. 400X magnification (scale bar, 0.7 mm).</p
Expression of SIRT1, Middle T Antigen, and ERα protein in mammary tumors.
<p>Representative immunohistochemical staining for SIRT1 (A-C), Middle T Antigen (D-F), and ERα (G-I) in mammary tumors collected at humane endpoint from <i>Sirt1</i><sup>+/+</sup>, <i>Sirt1</i><sup>Y/+</sup> and <i>Sirt1</i><sup>Y/Y</sup> mice at 200X magnification (scale bars, 100 μm).</p